The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of tivantinib monotherapy in patients with previously treated advanced or recurrent gastric cancer.
Kei Muro
No relevant relationships to disclose
Min-Hee Ryu
No relevant relationships to disclose
Hirofumi Yasui
No relevant relationships to disclose
Tomohiro Nishina
No relevant relationships to disclose
Baek-Yeol Ryoo
No relevant relationships to disclose
Narikazu Boku
No relevant relationships to disclose
Yoon-Koo Kang
Consultant or Advisory Role - Kyowa Hakko Kirin
Research Funding - Kyowa Hakko Kirin